The introduction of this vaccine represents a major advancement in the nation's battle against Hepatitis A, providing a substantial contribution to public health, according to a statement by the National Dairy Development Board (NDDB), a subsidiary of which IIL is.
Vaccine manufacturer Indian Immunologicals (IIL) marked a significant milestone with the launch of India's first domestically developed Hepatitis A vaccine, named 'Havisure.' The introduction of this vaccine represents a major advancement in the nation's battle against Hepatitis A, providing a substantial contribution to public health, according to a statement by the National Dairy Development Board (NDDB), a subsidiary of which IIL is.
Currently, India relies on imported Hepatitis A vaccines. The development of Havisure, after eight years of dedicated work, exemplifies the spirit of Atma Nirbhar Bharat (self-reliant India), as stated by K. Anand Kumar, Managing Director of IIL. The vaccine has undergone a comprehensive testing process, including pre-clinical toxicology studies in animals, a phase I trial in humans, and phase 2/3 trials across eight centers involving nearly 500 healthy volunteers of various age groups.
Havisure will be produced at IIL's Gachibowli plant in Hyderabad, with a primary focus on the domestic market. Kumar expressed the importance of achieving self-sufficiency and announced plans to manufacture 1 million doses annually, with potential for capacity expansion. The distribution network in India, coupled with exports to 50 countries, positions IIL as a global player. The company intends to seek WHO pre-qualification for Havisure, facilitating access to international markets.
The vaccine is priced at ₹2,150 per dose and is administered in two doses – the first above 12 months of age and the second at least six months later. Havisure is recommended for routine immunization in children and individuals at risk of exposure or traveling to regions with high Hepatitis A prevalence. Those with occupational infection risk and individuals with chronic liver diseases are also advised to undergo Hepatitis A vaccination.
Hepatitis A is a highly contagious viral infection primarily transmitted through the fecal-oral route, involving contaminated food or water. IIL's achievement in developing Havisure adds to its successful vaccine launches this year, including the measles and rubella vaccine and the TD vaccine. With an eye on global markets, IIL's commitment to self-sufficiency and public health is evident in this groundbreaking development.
